Client News

[PR Newswire] - SAN DIEGO, July 2, 2015 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP ("Robbins Geller") (http://www.rgrdlaw.com/cases/celladon/) today announced that a class action has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Celladon Corporation ("Celladon") (CLDN) publicly traded securities during the period between July 7, 2014 and June 25, 2015 (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from today. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff's counsel, Darren Robbins of Robbins Geller at 800/449-4900 or 619/231-1058, or via e-mail at djr@rgrdlaw.com. If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at http://www.rgrdlaw.com/cases/celladon/. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Posted: July 3, 2015, 2:00 am
[at noodls] - DUBLIN, Ohio--(BUSINESS WIRE)--Jul. 2, 2015-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) and its subsidiary, Macrophage Therapeutics, Inc., will hold a post-International Workshop on Kaposi's Sarcoma ...
Posted: July 2, 2015, 10:53 pm
[Business Wire] - The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Celladon Corporation common stock from July 7, 2014 through June 25, 2015, all dates inclusive.
Posted: July 2, 2015, 10:53 pm
[Business Wire] - Navidea Biopharmaceuticals, Inc. and its subsidiary, Macrophage Therapeutics, Inc., will hold a post-International Workshop on Kaposi's Sarcoma Herpesvirus and Related Agents conference webcast to provide investors with a more detailed look at the recently presented Manocept™ platform clinical and pre-clinical data and results disclosed in today’s press releases.
Posted: July 2, 2015, 10:12 pm
[GlobeNewswire] - PHILADELPHIA, July 02, 2015-- Law Offices Bernard M. Gross, P.C. today announces that it filed a class action lawsuit in the U. S. District Court for the Southern District of California, 15 cv01458, on ...
Posted: July 2, 2015, 8:17 pm
[Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, and Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 8, 2015, at 3:00 p.m.
Posted: July 2, 2015, 8:00 pm
[at noodls] - Bothell-Based Provider of Biopreservation Tools for Cells, Tissues, and Organs BOTHELL, WA - July 2, 2015 -BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary ...
Posted: July 2, 2015, 6:13 pm
Posted: July 2, 2015, 4:12 pm
Posted: July 2, 2015, 4:11 pm
[Business Wire] - Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. , today announced that preclinical results in Kaposi’s Sarcoma demonstrated that a cytotoxic drug, doxorubicin, linked to Manocept™ was targeted to and dose-dependently taken up in CD206+ KS tumor cells and tumor associated macrophages and caused apoptotic death of the KS tumor cells and TAMs.
Posted: July 2, 2015, 11:45 am
[at noodls] - - Reinforces Therapeutic Potential of Targeting Activated Macrophages via the CD206 Receptor- - Data also suggest a new origin of KS as a macrophage fusion tumor - DUBLIN, Ohio--(BUSINESS WIRE)--Jul. 2, ...
Posted: July 2, 2015, 11:43 am
[Business Wire] - Navidea Biopharmaceuticals, Inc. and its subsidiary, Macrophage Therapeutics, Inc., today announced that imaging results from the Manocept™ clinical trial in Kaposi’s Sarcoma and other preclinical studies were presented at the 18th International Workshop on Kaposi's Sarcoma Herpesvirus and Related Agents in Hollywood, Florida.
Posted: July 2, 2015, 11:30 am
[PR Newswire] - BOTHELL, Wash., July 2, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that Seattle Business Magazine has included BioLife in its annual list of the 100 best companies to work for in Washington state for 2015. Now in its 24th year, this competition salutes Washington companies setting the standard for leadership, strong benefits, ideal work environment, innovative training, happiest employees and more. Winners were recognized at an awards dinner held on July 1st at the Washington State Convention Center. Mike Rice, BioLife's Chief Executive Officer, commented, "Our entire team is very honored and proud to receive this recognition for the second time in three years. We have a very special corporate culture, based on merit, authentic communication, and teamwork.
Posted: July 2, 2015, 10:00 am
[at noodls] - Under the liquidity contract entrusted by Innate Pharma to Gilbert Dupont, the following assets appeared on the liquidity account as at June 30, 2015: - 26,811 shares of Innate Pharma, and - 334,840.22 ...
Posted: July 2, 2015, 8:53 am
[at noodls] - Half-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
Posted: July 1, 2015, 10:53 pm